Mmbg Investment Advisors CO. Has $1.02 Million Stake in AstraZeneca PLC (NASDAQ:AZN)

Mmbg Investment Advisors CO. lifted its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 86.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,879 shares of the company's stock after purchasing an additional 6,420 shares during the quarter. Mmbg Investment Advisors CO.'s holdings in AstraZeneca were worth $1,020,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Citizens National Bank Trust Department boosted its position in AstraZeneca by 3.2% during the first quarter. Citizens National Bank Trust Department now owns 27,094 shares of the company's stock valued at $1,991,000 after purchasing an additional 834 shares during the last quarter. Colonial River Investments LLC acquired a new position in shares of AstraZeneca during the 1st quarter worth approximately $267,000. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of AstraZeneca by 15.1% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 98,021 shares of the company's stock worth $7,205,000 after purchasing an additional 12,894 shares in the last quarter. Tsfg LLC boosted its holdings in shares of AstraZeneca by 138.4% in the 1st quarter. Tsfg LLC now owns 1,104 shares of the company's stock valued at $81,000 after buying an additional 641 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of AstraZeneca by 15.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 177,836 shares of the company's stock valued at $12,911,000 after buying an additional 24,141 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

Analyst Upgrades and Downgrades

Separately, BNP Paribas initiated coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $85.00.

AstraZeneca Stock Performance

AstraZeneca stock traded up $0.03 during midday trading on Monday, reaching $69.88. 3,701,381 shares of the company's stock were exchanged, compared to its average volume of 5,216,758. The stock's 50-day simple moving average is $70.59 and its 200 day simple moving average is $70.53. The firm has a market cap of $216.72 billion, a price-to-earnings ratio of 16.17, a P/E/G ratio of 1.28 and a beta of 0.38. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The company had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. During the same period in the previous year, the company posted $2.06 EPS. The firm's revenue for the quarter was up 7.2% compared to the same quarter last year. On average, analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.